The White House’s budget office is reviewing a Medicare Part D proposed rule that could include some of the president’s proposals to control drug prices, but the rule is no longer designated as economically significant. The regulatory agenda published this past spring said an economically significant Part D rule will be proposed in September. The change to the economic significance designation confuses lobbyists. There are multiple reasons the rule may not be listed as economically significant, according to Ross Margulies,...